
Index

A

Abdominal aortic aneurysm (AAA), 6
Abrams, P., 60
ADAM. *See* Androgen decline in aging male (ADAM)
Age-appropriate PHE. *See* Preventive health evaluation (PHE)
Albertsen, P.C., 141
Alexander, R.B., 30–32
Alfuzosin
 CPPS, 31
 LUTS, 58
Alpha-blockers
 CPPS, 29–33
 nonselective, LUTS
 doxazosin, 57–58
 prazosin, 56
 terazosin, 57–58
 selective (*see* Selective alpha blockers, LUTS)
5-Alpha reductase inhibitors (5ARIs), 59
American Cancer Society (ACS), 7–8
AMS Ambicor penile prosthesis®, 122, 123
AMS 700 CX inflatable penile prosthesis®, 122, 124
Anastomotic urethroplasty, 158
Anderson, R.U., 34
Androgen decline in aging male (ADAM)
 clinical presentation and diagnosis, 90–91
 epidemiology, 89–90
 TRT
 clinical benefits of, 93
 monitoring of patients, 92–93
 and prostate cancer, 93–94
 in USA, 91, 92
Angermeier, K.W., 163
Antibiotics, CPPS, 31, 33
Anti-inflammatories, CPPS, 31, 33
Antimuscarinics, 60
Antisperm antibodies, 174–175
5ARIs. *See* 5-Alpha reductase inhibitors (5ARIs)
Arousal/erection, 112
ART. *See* Assisted reproductive techniques (ART)
Arterial revascularization, 121

Artificial urinary sphincter (AUS)
 components, 135
 outcomes, 136–137
 surgical technique, 135–136
 surgical variations, 136
Aspirin, 5
Assisted reproductive techniques (ART), 177–178
Athanasopoulos, A., 62
AUS. *See* Artificial urinary sphincter (AUS)
Aversa, A., 19

B

Banithia, R., 202
Barrera, M., 196
Bates, S.M., 31
BCR. *See* Biochemical recurrence (BCR)
Beecher, H.K., 190
 Benign prostatic hyperplasia (BPH). *See also*
 Lower urinary tract symptoms (LUTS)
 AUA guidelines, 56, 57
 beta-sitosterol supplements, 77–79
 combination therapy, 61–63
 medications for, 56
 surgical treatment
 intraprostatic stents, 74
 laser therapy (*see* Laser therapy, BPH)
 open simple prostatectomy, 67–68
 TUIP, 73–74
 TUMT, 70–71
 TUNA, 69–70
 TURP, 68–69
Berglund, R.K., 163
Biochemical recurrence (BCR), 142, 143
Biopsychosocial relation diagram, 192
Bladder neck contracture (BNC), 132
Bladder outlet obstruction, 41
Blood pressure, 2
Botox, 133
Brachial artery FMD, 15, 17
Bruskewitz, R., 69, 70

Buccal mucosal graft onlay urethroplasty
 complications, 160
 indication, 158–159
 postoperative care, 160
 surgical technique, 159–160

C

Campo, B., 69
 Cancer of Prostate Risk Assessment (CAPRA), 143–144
 Carotid artery stenosis (CAS), 8
 Catheters, 43
 Celecoxib, 31, 33
 Cernilton, 32, 34
 Chapple, C., 56
 Cheah, P.Y., 30, 31
 Chen, Y., 31
 Cholesterol
 PHE, 2, 4
 reduction mechanisms, 77–79
 Chronic pain
 description, 189, 191
 and social support
 spouses, 197
 stress-buffering model, 197
 types, 196
 UCCPS, 197–199
 VZV, 9
 Chronic pelvic pain syndrome (CPPS)
 complementary medicine, 79–80
 monotherapies for
 antibiotics, 33
 anti-inflammatories, 33
 α -blockers, 29–33
 hormonal agents, 33
 neuroleptic, 34
 nonpharmacological therapy, 34
 phytotherapy, 33–34
 multifactorial etiology of, 29, 30
 NIH classification of, 29, 30
 UPOINT, 34–36
 Chronic prostatitis (CP). *See* Chronic pelvic pain syndrome (CPPS)
 Chronic scrotal content pain
 algorithm for, 185
 diagnosis, 182–183
 epidemiology and etiology, 181–182
 pathophysiology, 181–182
 surgical management, 185–187
 treatment, 183–186
 Chung, D.E., 63
 Ciprofloxacin, 31, 32
 Coloplast Titan inflatable penile prosthesis®, 122, 124
 Colorectal cancer, 6
 Complementary interventions
 bladder/kidney/prostate cancers, 80–81
 BPH/LUTS, 77–79
 chronic nonbacterial prostatitis, 79–80
 infertility, 81–82

sexual dysfunction, 82–83
 stones and urinary tract infections, 83
 Complicated urethroplasty
 long bulbar and panurethral strictures, 163–164
 PFUDDs, 164–165
 prostate cancer therapy, 166–167
 restenosis after urethral stent placement, 165–166
 urethral strictures after hypospadias repair, 162–163
 Cooperberg, M.R., 164
 Coronary heart disease (CHD) risk levels, 5
 Couples and prostate cancer, 201–202
 CPPS. *See* Chronic pelvic pain syndrome (CPPS)
 Cutaway diagram, EndoPAT device sensor, 16

D

Dalpiazz, O., 164
 D'Amico, A.V., 145
 D'Amico classification, 143, 145
 De Rose, A.F., 31
 Descartes' biomedical pain model, 190
 Detumescence, 14
 Diabetes, 4
 Digital plethysmography, vascular function, 15–18
 Dmochowski, R., 63
 Double graft technique, long bulbar urethral stricture, 163
 Doxazosin
 CPPS, 31, 32
 LUTS, 57–58
 Duloxetine, 132
 Dutasteride, 60

E

EBRT. *See* External-beam radiotherapy (EBRT)
 Eisenberg, M.L., 157, 165
 Eisenberg, R.A., 157
 Elist, J., 32
 Elliot, S.P., 166
 Endocrine causes, male infertility, 173–174
 Endo-PAT 2000 machine, 17
 Epididymectomy, 185
 Epididymitis
 definition, 181
 diagnosis, 182–183
 epidemiology and etiology, 181–182
 pathophysiology, 181–182
 Erectile dysfunction (ED)
 complementary interventions, 82–83
 consultation, 116–117
 CVD risk, 113
 design improvements, 126
 educational and psychosocial interventions, 113–114
 endothelial function
 assessment of, 15–18
 biomarkers, 18
 and cardiovascular risk, 19–20
 measurement of, 15

- physiologic considerations, 13–14
- practical considerations, 15
- testing, 20
- ultrasound-based measurement, FMD, 15
- follow-up, 116
- lifestyle and medication changes, 114
- management, 110–111
- next step after identification, 110
- partner satisfaction, 126–127
- patients and partners
 - sexual disorders, 109
 - sexual matter discussion, 108
- PDEIs, 115–116
- pharmacologic treatment, 114–115
- primary care evaluation
 - arousal/erection, 112
 - initial, 111
 - inquiry and management, 106–107
 - medications, 112
 - orgasm/ejaculation, 112
 - sex counseling, 110
 - sexual health, 105–106
- surgical treatment, 114–115
 - device coatings, 126
 - penile prosthesis implantation, 122
 - penile vascular surgery, 121–122

Esposito, K., 19

European Randomized Study of Screening or Prostate Cancer (ERSPC), 23–26

Evidence-based PHE. *See* Preventive health evaluation (PHE)

External-beam radiotherapy (EBRT), 148–149

F

Finasteride

- BPH, 59–60
- CPPS, 31, 32

FitzGerald, M.P., 32

Flouro-urodynamic image, overactive bladder, 132, 133

Flow-mediated dilatation (FMD), measurement of, 15

Follicle-stimulating hormone (FSH), 173

G

Gate control theory of pain, 190

Gelman, J., 166

Ginting, J.V., 198

Goldmeier, D., 31

Goldscheider, A., 190

Grade A and B recommendations, PHE, 7–8

Green light laser, 73

Gul, O., 31

H

Hanley, J.A., 24

Harvested and defatted buccal graft, 159

Holmium:YAG laser, 72–73

Hormonal agents, CPPS, 31, 33

Hourglass-deformity, 99

HPV vaccine. *See* Human papilloma virus (HPV) vaccine

Human immunodeficiency virus (HIV) screening, 6–7

Human papilloma virus (HPV) vaccine, 9

Hyperprolactinemia, 174

Hypogonadotropic hypogonadism (HH), 173–174

I

Ignarro, L.J., 13

Immunizations, recommended adult

- HPV vaccine, 9
- influenza vaccine, 9
- pneumococcal vaccine, 10
- Td and Tdap vaccines, 9
- VZV vaccine, 9–10

Infertility

- algorithm, for treatment, 172
- ART, 177–178
- complementary interventions, 81–82
- definition, 169
- medical treatment
 - antisperm antibodies, 174
 - endocrine causes, 173–174
 - retrograde ejaculation, 175
- presentation, 169–170
- surgical treatment
 - sperm delivery, 176–177
 - sperm production, 177
 - sperm retrieval, 175–176
- workup
 - indications, 171
 - male infertility, causes of, 171–172

Inflatable penile prostheses, 122–124

Influenza vaccine, 9

Intensive counseling, obese adults, 4

Interstitial cystitis (IC), 79–80

Intracytoplasmic sperm injection (ICSI), 177, 178

Intraprostatic stents, 74

Intrauterine insemination (IUI), 177, 178

In-vitro fertilization (IVF), 177, 178

IUI. *See* Intrauterine insemination (IUI)

J

Jeong, C.W., 32

Jeong, Y.B., 61

Johanson urethroplasty

- complications, 162
- indication, 161
- postoperative care, 162
- surgical technique, 161

K

Kamischke, A., 175

Kaplan, S.A., 62

Kawabe, K., 58
 Kershaw, T.S., 202
 Kirby, R.S., 56
 Klotz, L., 147

L

Lakey, B., 196, 198
 Laser therapy, BPH
 green light laser, 73
 holmium:YAG laser, 72–73
 Nd:YAG laser, 72
 Laumann, E., 111
 La Vignera, S., 19
 Lapor, H., 57, 58
 Leskinen, M., 31
 Leukocyte esterase, 40
 Levofloxacin
 acute epididymitis, 184
 CPPS, 31, 32
 LGX cylinders, 123, 125
 Localized prostate cancer
 history, 142–143
 risk stratification
 CAPRA, 143–144
 nomograms, 144
 progression-free probability, 145
 transperineal permanent interstitial
 brachytherapy, 149
 treatment guidelines
 active surveillance, 147
 ADT, 146
 EBRT, 148–149
 NCCN, 145
 primary androgen deprivation therapy, 150
 radical prostatectomy, 148
 Lower urinary tract symptoms (LUTS)
 alpha blockers, 56
 assessment of, 55–56
 beta-sitosterol supplements, 77–79
 bladder outlet obstruction
 evaluation, 42
 management, 42
 signs and symptoms, 41–42
 catheters, 43
 combination therapy, 61–63
 groups, 129
 nonselective alpha blockers
 doxazosin, 57–58
 prazosin, 56
 terazosin, 57–58
 phytotherapy, 56
 prevalence of, 129
 prophylaxis, 43–44
 selective alpha blockers
 alfuzosin, 58
 antimuscarinics, 60
 5ARIs, 59
 dutasteride, 60
 finasteride, 59–60

 naftopidil, 59
 PDE-5 inhibitors, 60–61
 silodosin, 58–59
 tamsulosin, 58
 LUTS. *See* Lower urinary tract symptoms (LUTS)

M

Malleable/rod penile prostheses, 122, 123
 Mangera, A., 163
 Manne, S.L., 201
 Marks, L.S., 58
 Massachusetts Male Aging Study, 89
 Mathur, R.K., 164
 MDSC. *See* Microdenervation of spermatic
 cord (MDSC)
 Meeks, J.J., 162
 Mehik, A., 31
 Mehrotra, A., 1
 Melzack, R., 191
 Meparticin, 31
 Microdenervation of spermatic cord (MDSC), 186
 Microsurgical (PESA) approach, 176
 Millard, R.J., 69
 Mulhall, J.P., 61

N

Naftopidil, 59
 Narayan, P., 58
 National Comprehensive Cancer Center Network
 (NCCN), 145
 Nd:YAG laser, 72
 Neurogenic hypothesis, 130
 Neuromatrix pain model, 191
 Nickel, J.C., 31
 Nitrite positivity, 40
 Nonpharmacological therapy, CPPS, 34
 Nonselective alpha blockers, LUTS
 doxazosin, 57–58
 prazosin, 56
 terazosin, 57–58

O

OAB. *See* Overactive bladder (OAB)
 Obesity, 4–5
 Open simple prostatectomy, 67–68
 Orandi, A., 73, 74
 Orgasm/ejaculation, 112
 Overactive bladder (OAB)
 behavioral therapies, 131
 definition, 129
 diagnosis and initial treatment
 behavioral therapies, 131
 medications, 131–132
 epidemiology, 129
 medications, 131–132
 pathophysiology, 130
 surgical treatment, 132–134

P

Pain

- and biomedical model, 189–192
- description, 189
- gating, 190, 191
- urogenital
 - description, 192–193
 - psychology of, 193–196

Pain catastrophizing scale items, 194

Palminteri, E., 163

PCA3, 27

PCSM. *See* Prostate cancer-specific mortality (PCSM)

PDEIs. *See* Phosphodiesterase type 5 inhibitors (PDEIs)

Pelvic fracture urethral distraction defects (PFUDDs), 164–165

Penedo, F.J., 201

Penile incontinence clamp, 132

Penile prosthesis implantation

- description, 122
- informed consent for, 124–126

Penile vascular surgery, 121–122

Pentosan polysulfate, 31, 33

Perceived support, 196

Percutaneous (PESA) approach, 176

Perineal slings, 134–135

Pertussis. *See* Whooping cough

Peyronie's disease

- anatomy of, 97, 98
- diagnostic evaluation, 98–100
- goals of therapy, 100
- management algorithm, 102
- treatment, 100–102

PFUDDs. *See* Pelvic fracture urethral distraction defects (PFUDDs)

PHE. *See* Preventive health evaluation (PHE)

Phosphodiesterase type 5 (PDE-5) inhibitors

- erectile dysfunction, 115–116
- LUTS, 60–61

Phytotherapy

- CPPS, 32–34
- LUTS, 56

Pneumococcal vaccine, 10

Pollen extract, 32–34

Pontari, M.A., 32

Porst, H., 61

Post hoc analysis, PLCO trial, 24

Post-vasectomy pain syndrome, 181–182

Post-void dribbling, 131

Prazosin, 56

Prednisolone, 31, 33

Pregabalin, 32, 34

Preventive health evaluation (PHE)

- abdominal aortic aneurysm, 6
- aspirin, to prevent CVD, 5
- blood pressure, 2
- cholesterol, 2, 4
- colorectal cancer, 6
- diabetes, 4
- grade A, B and D recommendations, 7–8
- human immunodeficiency virus screening, 6–7

immunizations

- HPV vaccine, 9
- influenza vaccine, 9
- pneumococcal vaccine, 10
- Td and Tdap vaccines, 9
- varicella zoster virus vaccine, 9–10

obesity and health diet counseling, 4–5

purpose of, 1

USPSTF A and B recommendations, 2, 3

Primary androgen deprivation therapy (ADT), 150

Prophylaxis, 43–44

Prostate cancer. *See* Localized prostate cancer

Prostate cancer prevention trial (PCPT), 24–26

Prostate cancer-specific mortality (PCSM), 141–143

Prostate specific antigen (PSA) screening

controversies

- overdiagnosis, of harmless cancers, 25
- prostate biopsy, 24
- randomized controlled trials, 23–24

opportunities

- biomarkers, 27
- diagnostic accuracy, 26
- risk calculator, 25–26
- testing, 26–27

Prostatitis

classification

- management, 49
- signs and symptoms, 47–48
- workup, 48–49

description, 47

Psychosocial factors, in urogenital conditions, 189.

See also Pain; Social support

Pyuria, 40

Q

Quercetin, 32–36

R

Radical prostatectomy, 148

Ramon, J., 69

Reactive hyperemia PAT (RH-PAT), 15–17, 19–20

Received support, 196

Referred pain, 181

Retrograde ejaculation, 175

Retropubic approach, 67

Rodriguez Jr, E., 166

Roehrborn, C.G., 58, 62, 69

Rofecoxib, 31, 33

Rosario, D.J., 69

S

Sacral neuromodulation (SNM), 133, 134

Sairam, K., 61

Santucci, R.A., 157

Saw palmetto, 56, 79

Scandinavian prostate cancer, 142

Schellhammer, P.F., 186

- Schulman, C.C., 69
 Sclerosing lymphangitis, 99
 Selective alpha blockers, LUTS
 alfuzosin, 58
 antimuscarinics, 60
 5ARIs, 59
 dutasteride, 60
 finasteride, 59–60
 naftopidil, 59
 PDE-5 inhibitors, 60–61
 silodosin, 58–59
 tamsulosin, 58
 Sex hormone binding globulin (SHBG), 90
 Sexually transmitted infections (STIs), 7
 Sharlip, I.D., 121
 Sharma, A., 164
 Sharpley, C.F., 201
 Shenfeld, O.Z., 164
 Shores, M.M., 90
 Shoskes, D.A., 32
 Silodosin, 58–59
 Sinclair, A.M., 184
 Sleep, D.J., 69
 SNM. *See* Sacral neuromodulation (SNM)
 Social integration, 196
 Social support
 and chronic pain
 spouses and social support, 197
 stress-buffering model, 197
 types, social support, 196
 UCCPS social support, 197–199
 and prostate cancer, 199–201
 Steele, G.S., 69
 Steenkamp, J.W., 156
 Stief, C.G., 62
 Stoner, E., 59
 Stress-buffering model, social support, 197
 Stress UI
 medications, 132
 surgical treatment, 134
 Suprapubic prostatectomy, 67
- T**
 Tamsulosin
 CPPS, 31, 32
 LUTS, 58
 Td and Tdap vaccine, 9
 Terazosin
 CPPS, 31
 LUTS, 57–58
 Testosterone replacement therapy (TRT)
 clinical benefits of, 93
 monitoring of patients, 92–93
 and prostate cancer, 93–94
 in USA, 91, 92
 Tetracycline hydrochloride, 31
 Tewari, A., 58
 Three-piece inflatable prostheses, with girth- and
 length-expanding cylinders, 123–124
- Transperineal permanent interstitial brachytherapy, 149
 Transurethral bulking agents, 134
 Transurethral incision of prostate (TUIP), 73–74
 Transurethral microwave therapy (TUMT), 70–71
 Transurethral needle ablation (TUNA), 69–70
 Transurethral resection of prostate (TURP), 68–69
 Transvesical prostatectomy, 67
 Tripp, D.A., 195
 TRT. *See* Testosterone replacement therapy (TRT)
 Tugcu, V., 30–32
 TUIP. *See* Transurethral incision of prostate (TUIP)
 TUMT. *See* Transurethral microwave therapy (TUMT)
 TUNA. *See* Transurethral needle ablation (TUNA)
 Tuncel, A., 63
 TURP. *See* Transurethral resection of prostate (TURP)
- U**
 UCCPS spousal support, 197–199
 UI. *See* Urinary incontinence (UI)
 Ultrax cylinders, 123, 125
 UPOINT
 description, 34
 diagnostic criteria, 36
 domains and associated therapies, 34, 35
 Upper urinary tract
 anatomic abnormalities, 46
 foreign objects, 46–47
 imaging, 45
 management, 45–46
 signs and symptoms, 44
 Ureterovesical reflux, 46
 Urethral strictures
 after hypospadias repair, 162–163
 anastomotic urethroplasty, 158
 anatomy, 155
 buccal mucosal graft onlay urethroplasty
 complications, 160
 indication, 158–159
 postoperative care, 160
 surgical technique, 159–160
 diagnosis and evaluation, 156
 etiology, 155–156
 johanson urethroplasty
 complications, 162
 indication, 161
 postoperative care, 162
 surgical technique, 161
 long bulbar and panurethral strictures, 163–164
 open reconstruction, 157
 PFUDDs, 164–165
 prostate cancer therapy, 166–167
 restenosis, 165–166
 treatment, 156
 urethral dilation and internal urethrotomy, 156–157
 urethral stents, 157
 Urethritis, 49–50
 Urethroplasty
 anastomotic, 158
 buccal mucosal graft onlay, 160

- complications, 160
 - indication, 158–159
 - surgical technique, 159–160
 - johanson (*see* Johanson urethroplasty)
 - Urinary incontinence (UI)
 - adjunctive measures, 132
 - behavioral therapies, 131
 - diagnosis and initial treatment
 - adjunctive measures, 132
 - behavioral therapies, 131
 - medications, 131–132
 - epidemiology, 129–130
 - medications, 132
 - pathophysiology, 130
 - surgical treatment
 - AUS (*see* Artificial urinary sphincter (AUS))
 - patient selection, 137
 - perineal slings, 134–135
 - transurethral bulking agents, 134
 - Urinary stasis, 41–43
 - Urinary tract infections (UTIs)
 - antibiotic therapy, 41
 - complementary interventions, 83
 - definition, 40
 - diagnosis of, 40
 - lower (*see* Lower urinary tract)
 - prevalence, 39
 - symptoms, 40
 - upper (*see* Upper urinary tract)
 - urinalysis, elements of, 40
 - Urodynamic testing, 132, 133
 - Urologic chronic pelvic pain syndromes (UCPPS), 192
 - Urolume stent, 166
 - Urotheliogenic mechanism, 130
 - US penile prostheses, 122, 123
- V**
- Varicella zoster virus (VZV) vaccine, 9–10
 - Varicocele grading system, 177
 - Veno-occlusive ED, surgery for, 121–122
 - Ventral urethrotomy and ventral buccal graft placement, 160
 - Vickers, A.J., 26
- W**
- Wagenlehner, F.M., 32
 - Wang, P., 164
 - Welch, H.G., 141
 - Whooping cough, 9
- X**
- Xu, Y.M., 164
- Y**
- Yamanishi, T., 58
 - Ye, Z.Q., 32
- Z**
- Zafirlukast, 31, 33
 - Zhao, T., 31
 - Zhou, Z., 31